ProCE Banner Activity

MCL3001 (RAY): Ibrutinib vs Temsirolimus in Previously Treated MCL

Slideset Download
Conference Coverage
Fewer AEs and significantly longer PFS and ORR with ibrutinib vs temsirolimus.

Released: December 09, 2015

Expiration: December 07, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Millennium Takeda

Seagen